CTD110.6 monoclonal antibody

Case ID:

C03770

C03770: CTD110.6 monoclonal antibody
Technical Details:
O-linked N-acetylglucosamine (O-GlcNAc) is a newly described but ubiquitous dynamic modification of key regulatory proteins in side virtually all multi-cellular eukaryotic cells. Recently, this sugar modification has been shown to be as abundant as protein phosphorylation, often competing with this key regulatory switch in the cell?s regulatory pathways. O-GlcNAc is now implicated to play an important role in diabetes, cancer and neurodegenerative diseases, such as Alzheimer?s Disease. The monoclonal antibody CTD110.6 is a valuable tool for the study of O-GlcNAc. This antibody specifically recognizes the modification on a wide variety of proteins in a manner that is analogous to the widely used antibodies to protein phosphorylation.
Looking for Partners:
Researchers interested in transcription, diabetes, tumor suppressors , oncogenes or cytoskeletal proteins. Potentially useful as a diagnostic tool, especially in diabetes and Alzheimer's Disease.

Direct Link:

https://jhu.technologypublisher.com/technology/18720

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Diabetes, Clinical and Disease Specializations > Metabolic Diseases, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Michael Woods

mwoods19@jh.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF